Beijing Innocare Pharma Tech Co., Ltd.

This trial is testing an experimental drug called ICP-723 for people with advanced solid tumors or brain tumors that have specific genetic changes called NTRK fusions. The study aims to see how well the drug shrinks tumors and controls cancer growth in about 70 participants who h…

This study is testing whether an oral medication called ICP-332 can effectively control moderate to severe atopic dermatitis (eczema) in adults. The trial will enroll 552 participants whose eczema hasn't responded well to standard topical treatments. Participants will receive eit…

This study is testing an experimental drug called ICP-248 for adults with mantle cell lymphoma, a type of blood cancer, that has returned or stopped responding to previous treatments. The trial will measure how well the drug shrinks tumors and controls the cancer, while monitorin…

This study is testing whether an investigational oral drug called ICP-332 can safely and effectively reduce the skin plaques and symptoms of moderate-to-severe psoriasis. About 172 adults with a significant history of psoriasis will be randomly assigned to receive either the real…

This is the first study in people to test a new drug called ICP-248, given alone or with another cancer drug, for adults with certain relapsed or hard-to-treat B-cell blood cancers. The main goals are to find a safe dose, see how the body processes the drug, and get an early look…

This early-stage study is testing a new drug called ICP-248, given alongside an existing drug (azacitidine), for adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goals are to find a safe dose and see how well the body handles the combination. …

This study is testing which of two different drug combinations works better for people whose marginal zone lymphoma has returned or stopped responding to previous treatment. Researchers will compare orelabrutinib plus rituximab against lenalidomide plus rituximab in 324 participa…

This study is testing an oral medication called ICP-488 to see if it can clear or nearly clear skin in adults with moderate to severe plaque psoriasis. About 383 participants will be randomly assigned to receive either the real drug or a placebo pill for 16 weeks. The main goal i…

This study is testing whether combining two drugs, ICP-248 and orelabrutinib, is safe and effective for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who haven't received treatment yet. Researchers will enroll about 226 adults to see how w…

This clinical trial is testing a new oral drug called ICP-723 in adults and adolescents with advanced solid tumors that cannot be surgically removed. The main goals are to find the safest dose, see how the body processes the drug, and check for any early signs that it might help …

This study is testing whether an investigational oral drug called ICP-332 can safely reduce severe itching and improve skin lesions in people with prurigo nodularis, a chronic skin condition. About 135 adults who have not gotten enough relief from standard creams will receive eit…